Radnet AI Stock Analysis
Radnet (PQIA) AI Stock Analysis
Radnet
(Frankfurt:PQIA)
No summary available
Radnet (PQIA) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 5.90B
- Dividend Yield
- ―
- Average Volume (3M)
- 65
- Price to Earnings (P/E)
- -261.6
- Beta (1Y)
- 0.43
- Revenue Growth
- 15.19%
- EPS Growth
- -35.09%
- Country
- Germany
- Employees
- 9,060
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Radnet Business Overview & Revenue Model
Company Description
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance...
Radnet Earnings Call Summary
The call was strongly positive. RadNet reported record company revenue and adjusted EBITDA, broad-based imaging volume growth, expanding advanced-imaging mix, raised Imaging Center and Digital Health guidance, strong liquidity, substantial Digital Health bookings and ARR growth, and continued progress in AI deployment and the planned ONRAD acquisition. The main challenges were year-over-year Digital Health EBITDA and margin declines, labor shortages, implementation seasonality and constraints, and expected 2027 Medicare reimbursement pressure, but management characterized the implementation constraints as resolved and remained confident about fourth-quarter and 2027 growth.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, Imaging Center segment total net revenue guidance is $2.385 billion to $2.435 billion, adjusted EBITDA guidance is $350 million to $363 million, capital expenditure guidance is $170 million to $180 million, and free cash flow guidance is $120 million to $130 million; Digital Health revenue guidance is $135 million to $145 million, while adjusted EBITDA guidance is $10 million to $13 million and adjusted EBITDA before noncapitalized R&D guidance is $11 million to $13 million, with Digital Health CapEx guidance increased by $1 million. Digital Health is on track for more than $140 million of ARR by year-end, roughly 87% growth over 2025, expects fourth quarter revenue to grow about 20% sequentially, and indicated a fully underpinned fourth quarter of well above $40 million; ONRAD is expected to add $190 million to $200 million of revenue and $60 million to $65 million of adjusted EBITDA in its first year of operation after closing. For 2027, RadNet estimated an approximately $5 million revenue impact from the final Medicare rule, while noting Congress may act to partially or fully reverse this reduction.
Radnet Risk Analysis
Radnet disclosed 48 risk factors in its most recent earnings report. Radnet reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksRadnet Peers Comparison
Overall Rating
DGX76Outperform
LH75Outperform
NEO54Neutral
OPK52Neutral
NDRA42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | $28.20B | 25.20 | 15.21% | 1.32% | 9.13% | 17.93% | |
| 75Outperform | $29.90B | 30.09 | 11.54% | 0.78% | 6.02% | 19.63% | |
| 54Neutral | $1.97B | -61.65 | -3.97% | ― | 11.08% | 71.76% | |
| 52Neutral | $1.20B | -8.41 | -12.41% | ― | -21.87% | 18.50% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | $5.88M | -0.62 | -224.80% | ― | ― | 60.87% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:PQIA | Radnet | 69.02 | 1.52 | 2.25% | |
| LH | Labcorp Holdings Inc. | 368.24 | 110.30 | 42.76% | |
| OPK | Opko Health | 1.62 | 0.31 | 23.66% | |
| DGX | Quest Diagnostics | 256.35 | 73.47 | 40.17% | |
| NEO | NeoGenomics Inc. | 15.25 | 4.97 | 48.35% | |
| NDRA | Endra Life Sciences | 3.92 | -2.73 | -41.05% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
